Cargando…
Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/ https://www.ncbi.nlm.nih.gov/pubmed/36785544 http://dx.doi.org/10.1155/2022/2668199 |
_version_ | 1784887485596172288 |
---|---|
author | Mehta, Yatin Mishra, K. C. Paliwal, Yashesh Rangappa, Pradeep Sinha, Sharmili Bhapkar, Sandeep |
author_facet | Mehta, Yatin Mishra, K. C. Paliwal, Yashesh Rangappa, Pradeep Sinha, Sharmili Bhapkar, Sandeep |
author_sort | Mehta, Yatin |
collection | PubMed |
description | Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well as Gram-negative bacteria. Levonadifloxacin has a well-defined mechanism of action involving a strong affinity for DNA gyrase as well as topoisomerase IV. Alalevonadifloxacin with widely differing solubility and oral bioavailability has pharmacokinetic profile identical to levonadifloxacin. Unlike existing MRSA drugs such as vancomycin and linezolid, which cause unfavorable side effects like nephrotoxicity, bone-marrow toxicity, and muscle toxicity, levonadifloxacin/alalevonadifloxacin has demonstrated superior safety and tolerability features with no serious adverse events. Levonadifloxacin/alalevonadifloxacin could be a useful weapon in the battle against infections caused by resistant microorganisms and could be a preferred antibiotic of choice for empirical therapy in the future. |
format | Online Article Text |
id | pubmed-9922174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-99221742023-02-12 Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin Mehta, Yatin Mishra, K. C. Paliwal, Yashesh Rangappa, Pradeep Sinha, Sharmili Bhapkar, Sandeep Crit Care Res Pract Review Article Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well as Gram-negative bacteria. Levonadifloxacin has a well-defined mechanism of action involving a strong affinity for DNA gyrase as well as topoisomerase IV. Alalevonadifloxacin with widely differing solubility and oral bioavailability has pharmacokinetic profile identical to levonadifloxacin. Unlike existing MRSA drugs such as vancomycin and linezolid, which cause unfavorable side effects like nephrotoxicity, bone-marrow toxicity, and muscle toxicity, levonadifloxacin/alalevonadifloxacin has demonstrated superior safety and tolerability features with no serious adverse events. Levonadifloxacin/alalevonadifloxacin could be a useful weapon in the battle against infections caused by resistant microorganisms and could be a preferred antibiotic of choice for empirical therapy in the future. Hindawi 2022-09-09 /pmc/articles/PMC9922174/ /pubmed/36785544 http://dx.doi.org/10.1155/2022/2668199 Text en Copyright © 2022 Yatin Mehta et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mehta, Yatin Mishra, K. C. Paliwal, Yashesh Rangappa, Pradeep Sinha, Sharmili Bhapkar, Sandeep Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title | Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title_full | Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title_fullStr | Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title_full_unstemmed | Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title_short | Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin |
title_sort | meeting the unmet need in the management of mdr gram-positive infections with oral bactericidal agent levonadifloxacin |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/ https://www.ncbi.nlm.nih.gov/pubmed/36785544 http://dx.doi.org/10.1155/2022/2668199 |
work_keys_str_mv | AT mehtayatin meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin AT mishrakc meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin AT paliwalyashesh meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin AT rangappapradeep meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin AT sinhasharmili meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin AT bhapkarsandeep meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin |